Biotech

All Articles

Analysts dig into Avidity's DMD win, showing subtleties in information

.Avidity Biosciences satisfied financiers along with phase 1/2 data in Duchenne muscle dystrophy (DM...

Actinogen's cortisol blocker falls short phase 2 anxiety research study

.Actinogen Medical's cortisol blocker has overlooked the primary endpoint of a phase 2 research in a...

Bivictrix determines going private only method to take ADC in to facility

.Antibody-drug conjugates (ADCs) have actually been at the center of many a billion-dollar biobuck l...

TPG leadings up funds to $580M for investments all over life sciences

.Asset supervisor TPG, which has supported biotechs like Sionna Therapies and Santa Clam Ana Biograp...

Merck quits phase 3 TIGIT test in bronchi cancer for futility

.Merck &amp Co.'s TIGIT program has actually gone through another setback. Months after shuttering a...

After a tough year, Exscientia folds into Recursion

.After a year described by pipe cuts, the shift of its chief executive officer and discharges, Exsci...

Cullinan, after $25M offer, restore bispecific to Harbour

.Cullinan Therapy was actually blown away good enough with Harbour BioMed's bispecific immune reacto...

A closer consider Ferocious Biotech's Ferocious 15

.In this full week's episode of "The Leading Line," we're diving into Intense Biotech's yearly Feroc...

Lilly deals with stage 2 failure of tau-targeting med

.The confetti is actually still flying from Eli Lilly's gathering commemorating the commendation of ...

Biogen CMO Maha Radhakrishnan signs up with Sofinnova-- Chutes &amp Ladders

.Welcome to recently's Chutes &amp Ladders, our roundup of considerable management hirings, shooting...